Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 317: Microtubule polymerizing effects of ellagic acid reduce efficacy of taxane chemotherapy

Jillian N. Eskra, Alaina Dodge and Maarten C. Bosland
Jillian N. Eskra
University of Illinois at Chicago, Chicago, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alaina Dodge
University of Illinois at Chicago, Chicago, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten C. Bosland
University of Illinois at Chicago, Chicago, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2016-317 Published July 2016
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

Abstract

Ellagic acid (EA) is a polyphenolic compound found in berries, pomegranates and other foods, which has cancer preventive and therapeutic properties. EA inhibits proliferation, induces apoptosis, blocks cell cycle progression and inhibits ABC drug transporters. Based on these anti-cancer activities of EA, we hypothesized that EA could enhance the efficacy of taxane chemotherapy on prostate cancer cells and inhibit drug resistance. We used castration-resistant 22Rv1, VCaP, and C4-2 prostate cancer cells and androgen-independent PC-3 cells to study effects of EA on efficacy of the taxane drug cabazitaxel (CBZ). Cells were treated with EA (0.1 μM - 30 μM) and after 72 hr proliferation was measured using the SRB assay. EA inhibited proliferation at levels greater than 10 μM. At 30 μM the greatest inhibition was observed in the most proliferative cell lines (22Rv1: 66.7%, PC-3: 82.7%), with a more modest effect on the slower growing cells (VCaP: 25.2%, C4-2: 31.7%). We next tested if growth inhibitory concentrations of EA could enhance the microtubule stabilizing effects of CBZ. In a cell-free assay, CBZ (1 nM - 1 μM) dose dependently increased tubulin polymerization, and EA (10 μM) increased polymerization by 61.0%. However, we observed an antagonistic response with the combination of CBZ and EA, reducing polymerized tubulin by 13.9% compared to CBZ alone. To confirm these results in cell culture, we treated 22Rv1 cells with EA (10 μM) and CBZ (10 nM) and determined levels of polymerized tubulin by western blotting. We observed a 1.6 fold increase in polymerized tubulin by EA, a 5.5 fold increase by CBZ, which was reduced to a 4.6 fold increase by combination of CBZ with EA. Contrary to our hypothesis, these results suggest that EA may interfere with taxanes, leading to a reduction in drug effectiveness. Additionally, the ability of EA alone to induce polymerization suggests the possibility that the growth inhibitory activity of EA is a consequence of its effects on microtubule dynamics, potentially through an interaction with taxane binding site of tubulin. This is consistent with our observation that EA has the greatest growth inhibitory effect on very proliferative cell lines, since microtubule targeting agents are most effective at killing rapidly dividing cells. To our knowledge, this is the first evidence of microtubule targeting as an anticancer mechanism of EA. We also studied the effects of EA on drug efflux to determine if EA could inhibit development of taxane drug resistance. We treated C4-2 cells with EA (0.01 μM - 30 μM) and measured calcein retention as marker of the activity of the P-glycoprotein (P-gp) pump. There was a dose dependent increase in calcein retention by EA, with a 1.9 fold increase at the highest concentration (30 μM), suggesting an inhibition of P-gp pump activity with increasing amounts of EA. Thus, EA may increase intracellular taxane levels, but at the same time reduce their microtubule-polymerization effects.

Citation Format: Jillian N. Eskra, Alaina Dodge, Maarten C. Bosland. Microtubule polymerizing effects of ellagic acid reduce efficacy of taxane chemotherapy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 317.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 76 (14 Supplement)
July 2016
Volume 76, Issue 14 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 317: Microtubule polymerizing effects of ellagic acid reduce efficacy of taxane chemotherapy
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 317: Microtubule polymerizing effects of ellagic acid reduce efficacy of taxane chemotherapy
Jillian N. Eskra, Alaina Dodge and Maarten C. Bosland
Cancer Res July 15 2016 (76) (14 Supplement) 317; DOI: 10.1158/1538-7445.AM2016-317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 317: Microtubule polymerizing effects of ellagic acid reduce efficacy of taxane chemotherapy
Jillian N. Eskra, Alaina Dodge and Maarten C. Bosland
Cancer Res July 15 2016 (76) (14 Supplement) 317; DOI: 10.1158/1538-7445.AM2016-317
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Mechanisms of Drug Resistance 1

  • Abstract 304: HER2 basal tumors have frequent mutation of HER3 and are more resistant to HER2-targeted therapy
  • Abstract 302: ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer
  • Abstract 292: Integrated analysis of ibrutinib resistance in chronic lymphocytic leukemia
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement